ASCO 2022: aanbevolen abstracten gerelateerd aan melanomen

25 juni 2022: ASCO 2022

Hier een aantal aanbevolen abstracten specifiek voor melanomen van ASCO 2022. Aanbevolen door verschillende artsen / oncologen uit de praktijk en zijn vaak ook werkend voor ASCO zelf. Klik op de nummers voor de studiepublicaties en presentaties.

Aanbevolen door Zeynep Eroglu, MD, a Medical Oncologist in the Department of Cutaneous Oncology at the Moffitt Cancer Center, and an Associate Editor for PracticeUpdate Center of Excellence for Advanced Melanoma, recommends the following abstracts to be presented at this year's ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.

Oral Abstract Session: Melanoma/Skin Cancers
Sunday, June 5, 2022; 10:45 AM–1:45 PM EDT

9501 Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. CU Blank, ILM Reijers, RPM Saw, et al

Take-Home Message

We will need randomized studies, but this single-arm phase II study shows that it may be feasible to safely omit therapeutic lymph node dissection after neoadjuvant immunotherapy in some patients with resectable stage III melanoma.

9502 Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512). KL Kendra, J Moon, Z Eroglu, et al

Take-Home Message

These results are practice-changing as we should strongly consider neoadjuvant anti–PD-1 immunotherapy for these rare desmoplastic melanomas, even those that are localized.

9506 Navtemadlin (KRT-232) activity after failure of anti-PD-1/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC). MKK Wong, MA Burgess, S Chandra, et al

9507 Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers. KM Schenk, JE Stein, S Chandra, et al

Take-Home Message

This is an important study looking at immunotherapy in organ transplant patients.
The response rate is low with PD-1 monotherapy, but perhaps the addition of ipilimumab will improve outcomes.

9508 A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM). L Si, C Li, X Bai, et al

Take-Home Message

Patients with metastatic acral melanoma have worse outcomes with anti–PD-1 therapy.
This combination of camrelizumab with apatinib and temozolomide may perhaps be more effective for them.

9515 Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study. R Dummer, P Queirolo, AM Abajo Guijarro, et al

Take-Home Message

This study offers promising results using a triplet regimen in patients with melanoma brain metastases, including symptomatic metastases.
The SWOG S2000 trial is randomizing the same patient population to a triplet regimen versus ipilimumab/nivolumab.

Poster Discussion Session: Melanoma/Skin Cancers
Monday, June 6, 2022; 5:30 PM–7:00 PM EDT

9510 FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). JS Zager, MM Orloff, PF Ferrucci, et al

Take-Home Message

Percutaneous hepatic perfusion may potentially be FDA-approved for patients with liver-dominant metastatic uveal melanoma.

9512 Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial. C Cui, B Lian, X Sheng, et al

9517 Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. M McKean, AW Tolcher, JA Reeves, et al

9519 Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). ND Gross, R Ferrarotto, M Amit, et al

Aanbevolen door

Dr. Roxana Dronca, Chair of the Mayo Clinic Division of Hematology/Oncology, and a member of the Advisory Board for PracticeUpdate Center of Excellence for Advanced Melanoma, recommends the following abstracts to be presented at this year's ASCO Annual Meeting, held June 3 through June 7, 2022, in Chicago and simultaneously online.

Oral Abstract Session: Developmental Therapeutics—Immunotherapy
Saturday, June 4, 2022; 2:15 PM–5:15 PM EDT

2500 Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. UN Vaishampayan, P Tomczak, J Muzaffar, et al

Oral Abstract Session: Melanoma/Skin Cancers
Sunday, June 5, 2022; 10:45 AM–1:45 PM EDT

9502 Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512). KL Kendra, J Moon, Z Eroglu, et al

Take-Home Message

Investigators explored if neoadjuvant anti–PD-1 monotherapy could induce pathologically confirmed regression in patients with resectable desmoplastic melanoma. In all, 28 patients with clinical evidence of residual disease were treated with pembrolizumab followed by surgery; no adjuvant treatment was offered.
Neoadjuvant pembrolizumab was associated with a high rate of pathological complete response (the primary endpoint); tolerance was considered excellent. These results indicate the feasibility of PD-1 blockade prior to surgery in this patient population.

9507 Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers. KM Schenk, JE Stein, S Chandra, et al

Take-Home Message

This is the first prospective clinical trial of nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/− ipilimumab (IPI) for kidney-transplant recipients with advanced cutaneous cancers. The primary composite endpoint was no tumor progression per RECIST v1.1 without allograft loss after NIVO for 16 weeks.
Among kidney-transplant recipients taking low-dose TACRO + PRED, although NIVO augmented tumor immune cell infiltration in some patients, it was not sufficient to mediate tumor regression. However, adding IPI enhanced anti-tumor immunity and mediated tumor regression.

Take-Home Message

The safety and efficacy of atezolizumab added to cobimetinib + vemurafenib was evaluated in cohort 2 of phase II of Tricotel inclusive of 65 melanoma patients with BRAFV600 mutations and CNS metastases. The cohort included symptomatic patients receiving corticosteroids but no patients having had prior systemic therapy for metastatic tumors. The primary outcome was the intracranial objective response rate. Serious adverse events occurred in 30% of the participants, a safety profile that is consistent with that seen in the IMspire150 study. Adverse events were associated with treatment discontinuation by 27% of participants.
Atezolizumab added to cobimetinib + vemurafenib had promising intracranial activity in patients with BRAFV600-mutated melanoma with CNS spread. Results were particularly encouraging in patients receiving corticosteroids and/or those with symptomatic CNS disease.

Poster Discussion Session: Melanoma/Skin Cancers
Monday, June 6, 2022; 5:30 PM–7:00 PM EDT

LBA9509 Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial). R Olofsson Bagge, A Nelson, A Shafazand, et al

ASCO 2022, aanbevolen abstracten, melanomen.